The World Health Organization (WHO) approved Covovax COVID-19 vaccine for emergency use. UN News reports.
The vaccine is produced by the Serum Institute of India, under licence from Novavax, and will now be part of the COVAX facility portfolio, boosting efforts to vaccinate more people in lower-income countries.
The WHO concluded that Covovax meets the organization’s standards for protection against COVID-19. It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.
This is already the ninth vaccine against COVID-19 approved by the WHO. Previously, vaccines from Modernа, Pfizer, Janssen (Johnson & Johnson), AstraZeneca, Chinese Sinopharm and Sinovac, as well as Indian Covaxin and Covishield were listed for emergency use.
The Russian Sputnik V coronavirus vaccine may be approved by WHO in the first quarter of 2022, TASS reported with reference to the WHO Regional Director for Europe Hans Kluge.
